Dana L Casey1,2,3, Kenneth L Pitter4, Leonard H Wexler5, Emily K Slotkin5, Gaorav P Gupta6,7, Suzanne L Wolden4. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. dana_casey@med.unc.edu. 2. Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, USA. dana_casey@med.unc.edu. 3. Lineberger Comprehensive Cancer Center, University of North Carolina Hospitals, Chapel Hill, NC, USA. dana_casey@med.unc.edu. 4. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Department of Pediatric Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 7. Lineberger Comprehensive Cancer Center, University of North Carolina Hospitals, Chapel Hill, NC, USA.
Abstract
BACKGROUND: p53 plays a key role in the DNA repair process and response to ionising radiation. We sought to determine the clinical phenotype of TP53 mutations and p53 pathway alterations in patients with rhabdomyosarcoma (RMS) and Ewing sarcoma (ES) treated with radiation. METHODS: Of patients with available genomic sequencing, we identified 109 patients with RMS and ES treated to a total of 286 radiation sites. We compared irradiated tumour control among tumours with TP53 mutations (n = 40) to those that were TP53 wild-type (n = 246). We additionally compared irradiated tumour control among tumours with any p53 pathway alteration (defined as tumours with TP53 mutations or TP53 wild-type tumours identified to have MDM2/4 amplification and/or CDKN2A/B deletion, n = 78) to those without such alterations (n = 208). RESULTS: The median follow-up was 26 months from radiation. TP53 mutations were associated with worse irradiated tumour control among the entire cohort (hazard ratio, HR = 2.8, P < 0.0001). Tumours with any p53 pathway alteration also had inferior irradiated tumour control (HR = 2.0, P = 0.003). On multivariable analysis, after controlling for tumour histology, intent of radiation, presence of gross disease, and biologically effective dose, TP53 mutations continued to be associated with a radioresistant phenotype (HR = 7.1, P < 0.0001). CONCLUSIONS: Our results show that TP53 mutations are associated with increased radioresistance in RMS and ES. Novel strategies to overcome this radioresistance are important for improved outcomes in p53 disruptive RMS and ES.
BACKGROUND: p53 plays a key role in the DNA repair process and response to ionising radiation. We sought to determine the clinical phenotype of TP53 mutations and p53 pathway alterations in patients with rhabdomyosarcoma (RMS) and Ewing sarcoma (ES) treated with radiation. METHODS: Of patients with available genomic sequencing, we identified 109 patients with RMS and ES treated to a total of 286 radiation sites. We compared irradiated tumour control among tumours with TP53 mutations (n = 40) to those that were TP53 wild-type (n = 246). We additionally compared irradiated tumour control among tumours with any p53 pathway alteration (defined as tumours with TP53 mutations or TP53 wild-type tumours identified to have MDM2/4 amplification and/or CDKN2A/B deletion, n = 78) to those without such alterations (n = 208). RESULTS: The median follow-up was 26 months from radiation. TP53 mutations were associated with worse irradiated tumour control among the entire cohort (hazard ratio, HR = 2.8, P < 0.0001). Tumours with any p53 pathway alteration also had inferior irradiated tumour control (HR = 2.0, P = 0.003). On multivariable analysis, after controlling for tumour histology, intent of radiation, presence of gross disease, and biologically effective dose, TP53 mutations continued to be associated with a radioresistant phenotype (HR = 7.1, P < 0.0001). CONCLUSIONS: Our results show that TP53 mutations are associated with increased radioresistance in RMS and ES. Novel strategies to overcome this radioresistance are important for improved outcomes in p53 disruptive RMS and ES.
Authors: E de Alava; C R Antonescu; A Panizo; D Leung; P A Meyers; A G Huvos; F J Pardo-Mindán; J H Healey; M Ladanyi Journal: Cancer Date: 2000-08-15 Impact factor: 6.860
Authors: M Luana Poeta; Judith Manola; Meredith A Goldwasser; Arlene Forastiere; Nicole Benoit; Joseph A Califano; John A Ridge; Jarrard Goodwin; Daniel Kenady; John Saunders; William Westra; David Sidransky; Wayne M Koch Journal: N Engl J Med Date: 2007-12-20 Impact factor: 91.245
Authors: Franck Tirode; Didier Surdez; Xiaotu Ma; Matthew Parker; Marie Cécile Le Deley; Armita Bahrami; Zhaojie Zhang; Eve Lapouble; Sandrine Grossetête-Lalami; Michael Rusch; Stéphanie Reynaud; Thomas Rio-Frio; Erin Hedlund; Gang Wu; Xiang Chen; Gaelle Pierron; Odile Oberlin; Sakina Zaidi; Gordon Lemmon; Pankaj Gupta; Bhavin Vadodaria; John Easton; Marta Gut; Li Ding; Elaine R Mardis; Richard K Wilson; Sheila Shurtleff; Valérie Laurence; Jean Michon; Perrine Marec-Bérard; Ivo Gut; James Downing; Michael Dyer; Jinghui Zhang; Olivier Delattre Journal: Cancer Discov Date: 2014-09-15 Impact factor: 39.397
Authors: Dana L Casey; Leonard H Wexler; Kenneth L Pitter; Robert M Samstein; Emily K Slotkin; Suzanne L Wolden Journal: Clin Cancer Res Date: 2019-11-07 Impact factor: 12.531
Authors: Nataliya Zhukova; Vijay Ramaswamy; Marc Remke; Dianna C Martin; Pedro Castelo-Branco; Cindy H Zhang; Michael Fraser; Ken Tse; Raymond Poon; David J H Shih; Berivan Baskin; Peter N Ray; Eric Bouffet; Peter Dirks; Andre O von Bueren; Elke Pfaff; Andrey Korshunov; David T W Jones; Paul A Northcott; Marcel Kool; Trevor J Pugh; Scott L Pomeroy; Yoon-Jae Cho; Torsten Pietsch; Marco Gessi; Stefan Rutkowski; Laszlo Bognár; Byung-Kyu Cho; Charles G Eberhart; Cecile Faure Conter; Maryam Fouladi; Pim J French; Wieslawa A Grajkowska; Nalin Gupta; Peter Hauser; Nada Jabado; Alexandre Vasiljevic; Shin Jung; Seung-Ki Kim; Almos Klekner; Toshihiro Kumabe; Boleslaw Lach; Jeffrey R Leonard; Linda M Liau; Luca Massimi; Ian F Pollack; Young Shin Ra; Joshua B Rubin; Erwin G Van Meir; Kyu-Chang Wang; William A Weiss; Karel Zitterbart; Robert G Bristow; Benjamin Alman; Cynthia E Hawkins; David Malkin; Steven C Clifford; Stefan M Pfister; Michael D Taylor; Uri Tabori Journal: Acta Neuropathol Commun Date: 2014-12-24 Impact factor: 7.801
Authors: Marwan Kwok; Nicholas Davies; Angelo Agathanggelou; Edward Smith; Ceri Oldreive; Eva Petermann; Grant Stewart; Jeff Brown; Alan Lau; Guy Pratt; Helen Parry; Malcolm Taylor; Paul Moss; Peter Hillmen; Tatjana Stankovic Journal: Blood Date: 2015-11-12 Impact factor: 22.113
Authors: Xiang Chen; Armita Bahrami; Alberto Pappo; John Easton; James Dalton; Erin Hedlund; David Ellison; Sheila Shurtleff; Gang Wu; Lei Wei; Matthew Parker; Michael Rusch; Panduka Nagahawatte; Jianrong Wu; Shenghua Mao; Kristy Boggs; Heather Mulder; Donald Yergeau; Charles Lu; Li Ding; Michael Edmonson; Chunxu Qu; Jianmin Wang; Yongjin Li; Fariba Navid; Najat C Daw; Elaine R Mardis; Richard K Wilson; James R Downing; Jinghui Zhang; Michael A Dyer Journal: Cell Rep Date: 2014-04-03 Impact factor: 9.423